NCT04004013 - Evaluate the Effect of Lifenol in Improving Bone Status in Postmenopausal Osteopenic Women | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

December 11, 2020

Study Completion Date

December 11, 2020

Conditions

Osteopenia, Generalized

Interventions

DIETARY_SUPPLEMENT

Lifenol®

"Lifenol®, powdered extract obtained from female hops flowers (Humulus lupulus L.) standardized in 8-PN content (100 µg /day) + maltodextrin = 500 mg/capsule~\+ 1000 mg of calcium and 800 IU of vitamin D per day"

DIETARY_SUPPLEMENT

Placebo

"Maltodextrin = 500 mg/capsule~\+ 1000 mg of calcium and 800 IU of vitamin D per day"

Trial Locations (1)

T23 R50R

Atlantia Food Clinical Trials, Cork